| 产品描述： | Miglustat hydrochloride is an inhibitor of glucosylceramide synthase and can be used for studies about Type I Gaucher disease. |
| 靶点： |
Transferase |
| 体内研究： |
Consumption of a standard high-fat breakfast within 30 minutes before administration of Miglustat hydrochloride significantly reduced peak exposure but did not significantly affect the extent of systemic exposure to Miglustat hydrochloride. The Cmax decreased by 36% on average following administration with food. AUC showed a modest (14%) decrease with food, but the 90% confidence interval was within the acceptance limit of 80% to 125%. Tmax was prolonged from 2.5 (1.0-4.0) hours in the fasted state to 4.5 (1.5-8.0) hours in the fed state, whereas the apparent terminal half-life was approximately 8 hours and not affected by food |
| 参考文献： |
1. van Giersbergen, P.L. and J. Dingemanse, Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase. J Clin Pharmacol, 2007. 47(10): p. 1277-82. 2. Abian, O., et al., Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase. Mol Pharm, 2011. 8(6): p. 2390-7. |
| 溶解性： |
Soluble in DMSO、H2O |
| 保存条件： |
-80℃（运输条件：冰袋低温运输） |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
3.91 ml |
19.551 ml |
39.102 ml |
| 5 mM |
0.782 ml |
3.91 ml |
7.82 ml |
| 10 mM |
0.391 ml |
1.955 ml |
3.91 ml |
| 50 mM |
0.078 ml |
0.391 ml |
0.782 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京